PH1-61 A PHASE 1 STUDY OF ABT-888 IN COMBINATION WITH CARBOPLATIN AND PACLITA

PH1-61 ABT-888 与卡铂和 PACLITA 联用的 1 期研究

• 批准号: 7982141
• 负责人: HEINZ JOSEF LENZ
• 金额: $ 0.12万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7982141
• 关键词: Carboplatin; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Dose; Funding; Grant; Institution; Molecular; Paclitaxel; Patients; Phase; Phase I Clinical Trials; Phase II Clinical Trials; Research; Research Personnel; Resources; Solid Neoplasm; Source; Toxic effect; United States National Institutes of Health

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this study is to determine the recommended dose for phase 2 studies of ABT-888 that can be given with carboplatin and paclitaxel in patients with advanced solid tumors. ABT-888 and paclitaxel doese will be escalated. The DLT and other toxicities will be defined. PK and molecular correlates will be done. ABT-889 is given orally bid on days 1-7. Carboplatin and paclitaxel will be given on day 3. USC will not participate in the MTD phase.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这项研究的主要目的是确定ABT-888的2阶段研究的建议剂量，这些剂量可以用卡泊素和紫杉醇在晚期实体瘤患者中给出。 ABT-888和Paclitaxel Doese将升级。将定义DLT和其他毒性。 PK和分子相关性将完成。 ABT-889在第1-7天口头出价。 Carboplatin和Paclitaxel将在第3天提供。USC将不参加MTD阶段。